0.8485
price up icon2.18%   0.0181
after-market After Hours: .89 0.0415 +4.89%
loading
I Mab Adr stock is traded at $0.8485, with a volume of 106.23K. It is up +2.18% in the last 24 hours and down -0.25% over the past month. I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
See More
Previous Close:
$0.8304
Open:
$0.8601
24h Volume:
106.23K
Relative Volume:
0.44
Market Cap:
$68.57M
Revenue:
$3.91M
Net Income/Loss:
$-206.53M
P/E Ratio:
-0.3418
EPS:
-2.4825
Net Cash Flow:
$-167.78M
1W Performance:
+0.85%
1M Performance:
-0.25%
6M Performance:
-36.20%
1Y Performance:
-52.86%
1-Day Range:
Value
$0.8305
$0.8998
1-Week Range:
Value
$0.8012
$0.8998
52-Week Range:
Value
$0.595
$2.00

I Mab Adr Stock (IMAB) Company Profile

Name
Name
I Mab Adr
Name
Phone
-
Name
Address
-
Name
Employee
32
Name
Twitter
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
IMAB's Discussions on Twitter

Compare IMAB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IMAB
I Mab Adr
0.8485 68.57M 3.91M -206.53M -167.78M -2.4825
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.42 124.91B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
587.85 60.05B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
594.65 35.88B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.97 29.83B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.13 24.58B 3.81B -644.79M -669.77M -6.24

I Mab Adr Stock (IMAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-09-21 Initiated Siebert Williams Shank Buy
Jun-02-21 Initiated Daiwa Securities Buy
Mar-15-21 Initiated Needham Buy
Mar-03-21 Reiterated H.C. Wainwright Buy
Feb-25-21 Initiated Piper Sandler Overweight
Dec-07-20 Initiated H.C. Wainwright Buy
Jul-27-20 Initiated Cantor Fitzgerald Overweight
Feb-12-20 Initiated China Renaissance Buy
Feb-11-20 Initiated Jefferies Buy
View All

I Mab Adr Stock (IMAB) Latest News

pulisher
Apr 14, 2025

After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance

Apr 14, 2025
pulisher
Apr 11, 2025

After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance

Apr 11, 2025
pulisher
Apr 07, 2025

I-Mab at Needham Conference: Strategic Transformation Unveiled - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

I-Mab at Needham Conference: Strategic Transformation Unveiled By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 04, 2025

I-Mab’s Transformative Year: Financial and Strategic Highlights - TipRanks

Apr 04, 2025
pulisher
Apr 04, 2025

I-Mab stock price target lowered to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

I-Mab stock price target lowered to $7 at H.C. Wainwright - Investing.com India

Apr 04, 2025
pulisher
Apr 03, 2025

I-Mab Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.

Apr 03, 2025
pulisher
Apr 03, 2025

I-Mab stock touches 52-week low at $0.72 amid market challenges - Investing.com

Apr 03, 2025
pulisher
Mar 21, 2025

I-Mab faces Nasdaq delisting over bid price rule By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

I-Mab faces Nasdaq delisting over bid price rule - Investing.com

Mar 21, 2025
pulisher
Mar 07, 2025

I-Mab advances gastric cancer treatment with swift trial enrollment - Investing.com

Mar 07, 2025
pulisher
Mar 05, 2025

I-Mab stock touches 52-week low at $0.76 amid market challenges - Investing.com India

Mar 05, 2025
pulisher
Feb 17, 2025

I-Mab ADR (IMAB) stock analysis: A simple moving average approach - US Post News

Feb 17, 2025
pulisher
Feb 07, 2025

Use of failure mode and effect analysis to improve the monoclonal antibody drugs management process in pharmacy intravenous admixture services - Nature

Feb 07, 2025
pulisher
Jan 08, 2025

I-Mab Chairman plans $2 million ADS purchase - Investing.com India

Jan 08, 2025
pulisher
Nov 23, 2024

I-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies - MSN

Nov 23, 2024
pulisher
Nov 06, 2024

I-Mab names Sean Fu as new CEO - Investing.com India

Nov 06, 2024
pulisher
Oct 30, 2024

Invitation: Vallourec Q3 2024 Results ReleaseConference Call on Friday, November 15, 2024 - The Manila Times

Oct 30, 2024
pulisher
Oct 28, 2024

I-Mab ADR (NASDAQ: IMAB) Stock: Investors Need To Know This - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Would I Buy Spectral AI Inc (NASDAQ: MDAI) Stock At Any Time In The Future? - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

If You Don’t Buy Hub Cyber Security Ltd (NASDAQ: HUBC) Now, You’ll Kick Yourself Later - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Itau Unibanco Holding S.A. ADR (NYSE: ITUB) Still Pointing Upwards - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Is Veritone Inc’s (NASDAQ:VERI) Stock On The Decline? - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Cisco Systems, Inc. (NASDAQ: CSCO): What’s Next After The Stock Plunge? - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Should This Give Tandem Diabetes Care Inc (NASDAQ: TNDM) Investors Sleepless Nights? - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Kinross Gold Corp. (NYSE: KGC) Investors Should Be Worried About This. - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Where Do Analysts See Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Heading? - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Not A Good News For Keycorp (NYSE: KEY): The Stock Could Go Down -34.98 Percent More - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Analyst Forecast For Grab Holdings Limited (NASDAQ: GRAB) - Stocks Register

Oct 28, 2024
pulisher
Oct 24, 2024

Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading - MSN

Oct 24, 2024
pulisher
Oct 09, 2024

IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance

Oct 09, 2024
pulisher
Sep 16, 2024

Piper Sandler maintains Overweight rating on I-Mab stock on drug data - Investing.com

Sep 16, 2024
pulisher
Mar 18, 2024

Piper Sandler cuts I-Mab stock target to $10, keeps overweight rating - Investing.com

Mar 18, 2024
pulisher
Mar 12, 2024

symbol__ Stock Quote Price and Forecast - CNN

Mar 12, 2024
pulisher
Sep 09, 2023

Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis - Nature

Sep 09, 2023
pulisher
Aug 17, 2023

I-Mab: Dropping Coverage - Morningstar

Aug 17, 2023
pulisher
Apr 12, 2023

I-Mab Full-Year Update Uneventful; Potential Catalysts in H2 2023 - Morningstar

Apr 12, 2023
pulisher
Mar 31, 2023

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 - PR Newswire

Mar 31, 2023
pulisher
Jan 03, 2023

Morningstar’s Best- and Worst-Performing Stocks: 2022 - Morningstar

Jan 03, 2023
pulisher
Dec 24, 2022

Results for A amyloid PET SUVr and B Centiloid scale assessments from study 201 core - ResearchGate

Dec 24, 2022
pulisher
Dec 23, 2022

The Cheapest Stock in the World - Morningstar.ca

Dec 23, 2022
pulisher
Dec 19, 2022

10 of the Cheapest Stocks of 2022 - Morningstar

Dec 19, 2022
pulisher
Nov 16, 2022

Why Are Some China Healthcare Stocks Up 50%? - HK.Morningstar.com

Nov 16, 2022
pulisher
Oct 21, 2022

Fig. 3 A Scatchard analysis of 125 I-trastuzumab binding to human... - ResearchGate

Oct 21, 2022
pulisher
Oct 13, 2022

Anti-ANGPTL3-FLD monoclonal antibody treatment ameliorates podocyte lesions through attenuating mitochondrial damage - Nature

Oct 13, 2022
pulisher
Oct 03, 2022

The Best- and Worst-Performing Stocks: Q3 2022 - Morningstar

Oct 03, 2022
pulisher
Jul 07, 2022

Fig. 2 Flowchart of Sicilian adverse drug reaction (ADR) report... - ResearchGate

Jul 07, 2022
pulisher
Jun 17, 2022

Markets Brief: How High Can Mortgage Rates Go? - Morningstar

Jun 17, 2022
pulisher
May 20, 2022

New 5-Star Stocks - Morningstar

May 20, 2022
pulisher
May 05, 2022

HFCAA News: 128 Chinese Stocks the SEC Could Delist - InvestorPlace

May 05, 2022

I Mab Adr Stock (IMAB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.13
price down icon 0.69%
$70.80
price down icon 0.62%
$31.69
price down icon 1.55%
$33.23
price up icon 21.50%
$114.83
price up icon 9.70%
biotechnology ONC
$249.13
price down icon 1.44%
Cap:     |  Volume (24h):